The 14 hemophilia treatment centers in Mid-Atlantic Region III provide data on their patient population annually. This data is reported to the federal grant agency (MCHB), and used by the Core Center for monitoring, budgeting and program planning.
Active patients by age, race and gender
In 2012, HTCs in the Mid-Atlantic Region III reported 3,150 active patients.
- 30% are female.
- 77% are Caucasian.
- 13% are African-American.
- 6% are Hispanic.
- 2% are Asian/Pacific Islander
Active patients by diagnosis
- Hemophilia A or B: 1,790 patients (57%).
- Von Willebrand disease: 1,149 patients (36%).
- 79% of female patients have von Willebrand disease.
Other factor deficiencies:
- 196 patients with a deficiency in factor I, II, V, VII, X, XI or XIII.
- These patients represent 6% of the patients in the region.
- 2,588 comprehensive evaluations were conducted at Mid-Atlantic Region III HTCs in 2012.
Primary Care Physicians (PCP):
- 2,575 patients Mid-Atlantic Region III had an identified PCP.
- 1,970 reports were sent from Mid-Atlantic Region III HTCs to PCPs.